Leveraging Transcriptional Readouts as a Platform for Drug Repurposing in Cardiomyopathy.
作者信息
Mahmoud Ahmed I, Sadek Hesham A
机构信息
Center for Cardiovascular and Muscular Diseases, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA (A.I.M.).
Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain (H.A.S.).
出版信息
Circulation. 2025 May 20;151(20):1449-1450. doi: 10.1161/CIRCULATIONAHA.125.074556. Epub 2025 May 19.
Abstract
摘要
相似文献
1
Leveraging Transcriptional Readouts as a Platform for Drug Repurposing in Cardiomyopathy.
Circulation. 2025 May 20;151(20):1449-1450. doi: 10.1161/CIRCULATIONAHA.125.074556. Epub 2025 May 19.
2
Sex, Survival, and Cardiomyopathy: Differences Between Men and Women With Hypertrophic Cardiomyopathy.
J Am Heart Assoc. 2019 Nov 5;8(21):e014448. doi: 10.1161/JAHA.119.014448. Epub 2019 Oct 30.
3
Human-induced pluripotent stem cells for modelling metabolic perturbations and impaired bioenergetics underlying cardiomyopathies.
Cardiovasc Res. 2021 Feb 22;117(3):694-711. doi: 10.1093/cvr/cvaa125.
4
Linking Clinical Parameters and Genotype in Dilated Cardiomyopathy.
Circ Heart Fail. 2018 Nov;11(11):e005459. doi: 10.1161/CIRCHEARTFAILURE.118.005459.
5
Reappraising Genes for Dilated Cardiomyopathy: Stepping Back to Move Forward.
Circulation. 2021 Jul 6;144(1):20-22. doi: 10.1161/CIRCULATIONAHA.121.054961.
6
Untangling the Biology of Genetic Cardiomyopathies with Pluripotent Stem Cell Disease Models.
Curr Cardiol Rep. 2017 Apr;19(4):30. doi: 10.1007/s11886-017-0842-1.
7
Global and Regional Longitudinal Strain Assessment in Hypertrophic Cardiomyopathy.
Circ Cardiovasc Imaging. 2019 Aug;12(8):e009586. doi: 10.1161/CIRCIMAGING.119.009586. Epub 2019 Aug 15.
8
Genetic Spectrum of Arrhythmogenic Cardiomyopathy.
Circ Heart Fail. 2019 Mar;12(3):e005850. doi: 10.1161/CIRCHEARTFAILURE.119.005850.
9
Hypertrophic Cardiomyopathy.
Circulation. 2018 Oct 2;138(14):1399-1401. doi: 10.1161/CIRCULATIONAHA.118.035932.
10
Is There a Role for Intravenous Stem Cell Delivery in Nonischemic Cardiomyopathy?
Circ Res. 2017 Jan 20;120(2):256-258. doi: 10.1161/CIRCRESAHA.116.310342.
本文引用的文献
1
Olmesartan Restores Function in Haploinsufficient Cardiomyocytes.
Circulation. 2025 May 20;151(20):1436-1448. doi: 10.1161/CIRCULATIONAHA.121.058621. Epub 2025 Apr 1.
2
Rare Variant Genetics and Dilated Cardiomyopathy Severity: The DCM Precision Medicine Study.
Circulation. 2023 Sep 12;148(11):872-881. doi: 10.1161/CIRCULATIONAHA.123.064847. Epub 2023 Aug 29.
3
Activation of PDGF pathway links LMNA mutation to dilated cardiomyopathy.
Nature. 2019 Aug;572(7769):335-340. doi: 10.1038/s41586-019-1406-x. Epub 2019 Jul 17.
4
A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles.
Cell. 2017 Nov 30;171(6):1437-1452.e17. doi: 10.1016/j.cell.2017.10.049.
5
Modeling of lamin A/C mutation premature cardiac aging using patient‐specific induced pluripotent stem cells.
Aging (Albany NY). 2012 Nov;4(11):803-822. doi: 10.18632/aging.100503.
6
Activation of MAPK pathways links LMNA mutations to cardiomyopathy in Emery-Dreifuss muscular dystrophy.
J Clin Invest. 2007 May;117(5):1282-93. doi: 10.1172/JCI29042. Epub 2007 Apr 19.
7
Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation.
Nat Genet. 2004 Mar;36(3):257-63. doi: 10.1038/ng1305. Epub 2004 Feb 8.
8
Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease.
N Engl J Med. 1999 Dec 2;341(23):1715-24. doi: 10.1056/NEJM199912023412302.
Zotero 插件